Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NCT00661427 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

61

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck
Squamous Cell Cancer

Interventions

BIOLOGICAL: cetuximab
BIOLOGICAL: cetuximab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]